{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:24:19Z","timestamp":1791923059062,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bladder cancer progression is frequently accompanied by metabolic reprogramming and immune escape, yet how these processes are coupled remains unclear. Sterol regulatory element-binding transcription factor 1 (SREBF1) governs lipid homeostasis and is often deregulated in cancer. We find that SREBF1 is upregulated in human bladder tumours and associates with invasion, metastasis and poor patient outcome, critically, it sustains tumor growth by driving immune evasion. Mechanistically, SREBF1 directly interacts with the SUMO E3 ligase TRIM28, which catalyses SUMO2 conjugation of SREBF1 at K470, antagonizes K48-linked ubiquitination and stabilizes SREBF1. TRIM28 further enhances SREBF1 occupancy at the MGAT4A promoter and upregulates MGAT4A, thereby promoting N-linked glycosylation of PD-L1, which stabilizes PD-L1 and increases its plasma-membrane localization, dampening CD8\u2009+\u2009T-cell cytotoxicity. In immunocompetent mice, TRIM28 knockdown reduces tumor growth, lowers PD-L1 and increases CD8\u2009+\u2009T-cell infiltration\u2014effects reversed by SREBF1 overexpression; in an immune-augmented human PDX model, SREBF1 targeting synergizes with anti\u2013PD-1 without overt toxicity. These findings identify a TRIM28\u2013SREBF1\u2013MGAT4A axis that couples lipid metabolic rewiring to immune-checkpoint regulation via PD-L1 N-glycosylation, positioning SREBF1 as a biomarker for BCa progression and risk stratification and as a druggable node to potentiate PD-1 blockade.<\/jats:p>","DOI":"10.1038\/s41419-026-08798-8","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:27:12Z","timestamp":1779085632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TRIM28-mediated SUMOylation of SREBF1 drives PD\u2011L1 N\u2011glycosylation and immune evasion in bladder cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Ru","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhe","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"8798_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","volume":"66","author":"Z Kirkali","year":"2005","unstructured":"Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4\u201334.","journal-title":"Urology"},{"key":"8798_CR2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","volume":"69","author":"J Dobruch","year":"2016","unstructured":"Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69:300\u201310.","journal-title":"Eur Urol"},{"key":"8798_CR3","doi-asserted-by":"crossref","unstructured":"Martinez Rodriguez RH, Buisan Rueda O, Ibarz L. Bladder cancer: present and future. Med Clin. 2017;149:449-55.","DOI":"10.1016\/j.medcle.2017.10.005"},{"key":"8798_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCO.0b013e3283446a11","volume":"23","author":"TM Morgan","year":"2011","unstructured":"Morgan TM, Keegan KA, Clark PE. Bladder cancer. Curr Opin Oncol. 2011;23:275\u201382.","journal-title":"Curr Opin Oncol"},{"key":"8798_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G, et al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79:82\u2013104.","journal-title":"Eur Urol"},{"key":"8798_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ccell.2021.04.012","volume":"39","author":"M Knowles","year":"2021","unstructured":"Knowles M, Dyrskj\u00f8t L, Heath EI, Bellmunt J, Siefker-Radtke AO. Metastatic urothelial carcinoma. Cancer Cell. 2021;39:583\u20135.","journal-title":"Cancer Cell"},{"key":"8798_CR7","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1080\/08820139.2022.2118606","volume":"51","author":"DF Ward Grados","year":"2022","unstructured":"Ward Grados DF, Ahmadi H, Griffith TS, Warlick CA. Immunotherapy for bladder cancer: latest advances and ongoing clinical trials. Immunol Invest. 2022;51:2226\u201351.","journal-title":"Immunol Invest"},{"key":"8798_CR8","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. Bmj. 2024;384:e076743.","journal-title":"Bmj"},{"key":"8798_CR9","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/15548627.2023.2275501","volume":"20","author":"F Geng","year":"2024","unstructured":"Geng F, Guo D. SREBF1\/SREBP-1 concurrently regulates lipid synthesis and lipophagy to maintain lipid homeostasis and tumor growth. Autophagy. 2024;20:1183\u20135.","journal-title":"Autophagy"},{"key":"8798_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13046-022-02583-z","volume":"42","author":"X Chen","year":"2023","unstructured":"Chen X, Yong H, Chen M, Deng C, Wang P, Chu S, et al. TRIM21 attenuates renal carcinoma lipogenesis and malignancy by regulating SREBF1 protein stability. J Exp Clin Cancer Res. 2023;42:34.","journal-title":"J Exp Clin Cancer Res"},{"key":"8798_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07404-7","volume":"16","author":"M Zhang","year":"2025","unstructured":"Zhang M, Bai J, Yuan H, Duan X, Yu L, Li Y, et al. BRD1 deficiency affects SREBF1-related lipid metabolism through regulating H3K9ac\/H3K9me3 transition to inhibit HCC progression. Cell Death Dis. 2025;16:104.","journal-title":"Cell Death Dis"},{"key":"8798_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","volume":"89","author":"MS Brown","year":"1997","unstructured":"Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331\u201340.","journal-title":"Cell"},{"key":"8798_CR13","doi-asserted-by":"crossref","unstructured":"Dadey RE, Li R, Griner J, Chen J, Singh A, Isett B, et al. Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma. J Immunother Cancer. 2025;13.","DOI":"10.1136\/jitc-2025-011537"},{"key":"8798_CR14","first-page":"1081","volume":"52","author":"ZJ Han","year":"2018","unstructured":"Han ZJ, Feng YH, Gu BH, Li YM, Chen H. The post-translational modification, SUMOylation, and cancer (Review). Int J Oncol. 2018;52:1081\u201394.","journal-title":"Int J Oncol"},{"key":"8798_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/CCO.0000000000000765","volume":"33","author":"L Du","year":"2021","unstructured":"Du L, Liu W, Rosen ST. Targeting SUMOylation in cancer. Curr Opin Oncol. 2021;33:520\u20135.","journal-title":"Curr Opin Oncol"},{"key":"8798_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12929-017-0374-4","volume":"24","author":"P Czerwi\u0144ska","year":"2017","unstructured":"Czerwi\u0144ska P, Mazurek S, Wiznerowicz M. The complexity of TRIM28 contribution to cancer. J Biomed Sci. 2017;24:63.","journal-title":"J Biomed Sci"},{"key":"8798_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25033-4","volume":"12","author":"Y Qin","year":"2021","unstructured":"Qin Y, Li Q, Liang W, Yan R, Tong L, Jia M, et al. TRIM28 SUMOylates and stabilizes NLRP3 to facilitate inflammasome activation. Nat Commun. 2021;12:4794.","journal-title":"Nat Commun"},{"key":"8798_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44502-6","volume":"15","author":"J Ren","year":"2024","unstructured":"Ren J, Wang S, Zong Z, Pan T, Liu S, Mao W, et al. TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence. Nat Commun. 2024;15:244.","journal-title":"Nat Commun"},{"key":"8798_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","volume":"33","author":"CW Li","year":"2018","unstructured":"Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33:187\u2013201.e10.","journal-title":"Cancer Cell"},{"key":"8798_CR20","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/s41418-024-01432-0","volume":"32","author":"X Guo","year":"2025","unstructured":"Guo X, Cui T, Sun L, Fu Y, Cheng C, Wu C, et al. A STT3A-dependent PD-L1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma. Cell Death Differ. 2025;32:944\u201358.","journal-title":"Cell Death Differ"},{"key":"8798_CR21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.biochi.2004.09.018","volume":"86","author":"D Eberl\u00e9","year":"2004","unstructured":"Eberl\u00e9 D, Hegarty B, Bossard P, Ferr\u00e9 P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004;86:839\u201348.","journal-title":"Biochimie"},{"key":"8798_CR22","doi-asserted-by":"publisher","first-page":"210050","DOI":"10.1098\/rsob.210050","volume":"11","author":"Z Sheng","year":"2021","unstructured":"Sheng Z, Zhu J, Deng YN, Gao S, Liang S. SUMOylation modification-mediated cell death. Open Biol. 2021;11:210050.","journal-title":"Open Biol"},{"key":"8798_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41392-020-0196-9","volume":"5","author":"L Chen","year":"2020","unstructured":"Chen L, Liu S, Tao Y. Regulating tumor suppressor genes: post-translational modifications. Signal Transduct Target Ther. 2020;5:90.","journal-title":"Signal Transduct Target Ther"},{"key":"8798_CR24","unstructured":"Maeda K, Taniguchi N. Enzyme assay of N-acetylglucosaminyltransferase-IV (GnT-IVa,b, MGAT4A,B). In: Nishihara S, Angata K, Aoki-Kinoshita KF, Hirabayashi J, editors. Glycoscience Protocols (GlycoPODv2). Saitama (JP): Japan Consortium for Glycobiology and Glycotechnology; 2021."},{"key":"8798_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1139\/o03-090","volume":"82","author":"R McPherson","year":"2004","unstructured":"McPherson R, Gauthier A. Molecular regulation of SREBP function: the Insig-SCAP connection and isoform-specific modulation of lipid synthesis. Biochem Cell Biol. 2004;82:201\u201311.","journal-title":"Biochem Cell Biol"},{"key":"8798_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0083-6729(02)65064-2","volume":"65","author":"H Shimano","year":"2002","unstructured":"Shimano H. Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism. Vitam Horm. 2002;65:167\u201394.","journal-title":"Vitam Horm"},{"key":"8798_CR27","doi-asserted-by":"publisher","first-page":"31189","DOI":"10.1073\/pnas.2017152117","volume":"117","author":"J Yi","year":"2020","unstructured":"Yi J, Zhu J, Wu J, Thompson CB, Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci USA. 2020;117:31189\u201397.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8798_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-024-03053-4","volume":"43","author":"T Xu","year":"2024","unstructured":"Xu T, Li X, Zhao W, Wang X, Jin L, Feng Z, et al. SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis. J Exp Clin Cancer Res. 2024;43:126.","journal-title":"J Exp Clin Cancer Res"},{"key":"8798_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s12944-024-02360-1","volume":"23","author":"Z Wang","year":"2024","unstructured":"Wang Z, Wan X, Khan MA, Peng L, Sun X, Yi X, et al. NAT10 promotes liver lipogenesis in mouse through N4-acetylcytidine modification of Srebf1 and Scap mRNA. Lipids Health Dis. 2024;23:368.","journal-title":"Lipids Health Dis"},{"key":"8798_CR30","doi-asserted-by":"publisher","first-page":"100888","DOI":"10.1016\/j.jlr.2025.100888","volume":"66","author":"S Rajakumari","year":"2025","unstructured":"Rajakumari S, Divakaran SJ. EBF2 regulates cardiolipin and phosphatidylethanolamine remodeling and mitochondrial dynamics in brown fat. J Lipid Res. 2025;66:100888.","journal-title":"J Lipid Res"},{"key":"8798_CR31","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s12035-016-9773-x","volume":"54","author":"Y Chen","year":"2017","unstructured":"Chen Y, Bang S, McMullen MF, Kazi H, Talbot K, Ho MX, et al. Neuronal activity-induced sterol regulatory element binding protein-1 (SREBP1) is disrupted in dysbindin-null mice-potential link to cognitive impairment in schizophrenia. Mol Neurobiol. 2017;54:1699\u2013709.","journal-title":"Mol Neurobiol"},{"key":"8798_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41392-023-01450-3","volume":"8","author":"X Ma","year":"2023","unstructured":"Ma X, Jia S, Wang G, Liang M, Guo T, Du H, et al. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance. Signal Transduct Target Ther. 2023;8:246.","journal-title":"Signal Transduct Target Ther"},{"key":"8798_CR33","doi-asserted-by":"crossref","unstructured":"Li L, Yang J, Li F, Gao F, Zhu L, Hao J. FBXW7 mediates high glucose\u2011induced SREBP\u20111 expression in renal tubular cells of diabetic nephropathy under PI3K\/Akt pathway regulation. Mol Med Rep. 2021;23.","DOI":"10.3892\/mmr.2021.11872"},{"key":"8798_CR34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.cmet.2024.01.011","volume":"36","author":"S Rong","year":"2024","unstructured":"Rong S, Xia M, Vale G, Wang S, Kim CW, Li S, et al. DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER. Cell Metab. 2024;36:617\u201329.e7.","journal-title":"Cell Metab"},{"key":"8798_CR35","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-020-2183-2","volume":"580","author":"D Xu","year":"2020","unstructured":"Xu D, Wang Z, Xia Y, Shao F, Xia W, Wei Y, et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1\/2 for lipogenesis. Nature. 2020;580:530\u20135.","journal-title":"Nature"},{"key":"8798_CR36","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-023-02711-3","volume":"42","author":"Y Cui","year":"2023","unstructured":"Cui Y, Li J, Zhang P, Yin D, Wang Z, Dai J, et al. B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma. J Exp Clin Cancer Res. 2023;42:146.","journal-title":"J Exp Clin Cancer Res"},{"key":"8798_CR37","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.7150\/thno.52435","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Gao A, Zhang F, Yang Z, Wang S, Fang Y, et al. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Theranostics. 2021;11:3392\u2013416.","journal-title":"Theranostics"},{"key":"8798_CR38","doi-asserted-by":"publisher","first-page":"100987","DOI":"10.1016\/j.drup.2023.100987","volume":"70","author":"WJ Liu","year":"2023","unstructured":"Liu WJ, Wang L, Zhou FM, Liu SW, Wang W, Zhao EJ, et al. Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8\/PD-L1 signaling in NSCLC. Drug Resist Updat. 2023;70:100987.","journal-title":"Drug Resist Updat"},{"key":"8798_CR39","doi-asserted-by":"publisher","first-page":"6633","DOI":"10.1007\/s11033-022-07246-y","volume":"49","author":"R Qiu","year":"2022","unstructured":"Qiu R, Wang W, Li J, Wang Y. Roles of PTEN inactivation and PD-1\/PD-L1 activation in esophageal squamous cell carcinoma. Mol Biol Rep. 2022;49:6633\u201345.","journal-title":"Mol Biol Rep"},{"key":"8798_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06921-1","volume":"15","author":"W Zhang","year":"2024","unstructured":"Zhang W, Zhao E, Li Z, Liu W, Wang J, Hou W, et al. Hexokinase HK3-mediated O-GlcNAcylation of EP300: a key regulator of PD-L1 expression and immune evasion in ccRCC. Cell Death Dis. 2024;15:613.","journal-title":"Cell Death Dis"},{"key":"8798_CR41","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.4049\/jimmunol.1203561","volume":"190","author":"C Huang","year":"2013","unstructured":"Huang C, Martin S, Pfleger C, Du J, Buckner JH, Bluestone JA, et al. Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1\/TRIM28. J Immunol. 2013;190:4470\u20133.","journal-title":"J Immunol"},{"key":"8798_CR42","doi-asserted-by":"publisher","first-page":"e02313","DOI":"10.7554\/eLife.02313","volume":"3","author":"RW Serra","year":"2014","unstructured":"Serra RW, Fang M, Park SM, Hutchinson L, Green MR. A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. Elife. 2014;3:e02313.","journal-title":"Elife"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08798-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:52:30Z","timestamp":1786020750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08798-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8798"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08798-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"693"}}